Carcinoma of the Esophagus in Patient With Psoriasis: A Case Report

Main Article Content

Likhasit Sanglutong
Noppawan Vipatakul
Somchai Insiripong
Kasipot K.Seesuvan


Psoriasis is an immune-mediated, genetic inflammatory disease predominantly affecting the skin and joints. Although various cancers including lymphoma, nonmelanoma skin cancer, and lung cancer among psoriasis patients are more commonly found than the general population; carcinoma of the esophagus has never been reported. The aim of this report was to describe a case of carcinoma of esophagus that was diagnosed in a psoriatic patient. A 50-year-old Thai male presented with epigastric fullness, progressive dysphagia, vomiting, and weight loss for 2 kg within one month. Physical examination revealed multiple erythematous plaques 1 - 3 cm on the trunk and limbs. He had been diagnosed as psoriasis for a year and treated with topical creams. The esophagoscopy revealed the cancer at the lower end of the esophagus that was proved to be poorly to moderately differentiated carcinoma. The computerized tomography of the chest including the upper abdomen showed the esophageal tumor abutting the left bronchus and aorta with multiple lymphadenopathy. He was diagnosed with T3N2M1 stage that was treated with supportive gastrostomy followed by palliative radiotherapy and chemotherapy. Because the carcinoma of esophagus has been hardly reported in psoriatic patients, it could not be easily concluded whether these two entities may have relationship or they just happen by chance.


Article Details

How to Cite
Sanglutong, L., Vipatakul, N., Insiripong, S., & K.Seesuvan, K. (2019). Carcinoma of the Esophagus in Patient With Psoriasis: A Case Report. Ramathibodi Medical Journal, 42(2), 79 - 84.
Case Reports


1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. doi:10.1016/S0140-6736(14)61909-7.

2. Raut AS, Prabhu RH, Patravale VB. Psoriasis clinical implications and treatment: a review. Crit Rev Ther Drug Carrier Syst. 2013;30(3):183-216. doi:10.1615/CritRevTherDrugCarrierSyst.2013005268.

3. Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN, Mule PM. Psoriasis: a comprehensive review. Int J Pharm Life Sci. 2011;2(6):857-877.

4. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-285.

5. De Rosa G, Mignogna C. The histopathology of psoriasis. Reumatismo. 2007;59 (Suppl 1):46-48.

6. Rahman M, Alam K, Ahmad MZ, et al. Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord Drug Targets. 2012;12(3):287-302. doi:10.2174/187153012802002901.

7. Liu JT, Yeh HM, Liu SY, Chen KT. Psoriatic arthritis: epidemiology, diagnosis, and treatment. World J Orthop. 2014;5(4):537-543. doi:10.5312/wjo.v5.i4.537.

8. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152(3):282-290. doi:10.1001/jamadermatol.2015.4847.

9. Akaraphanth R, Kwangsukstid O, Gritiyarangsan P, Swanpanyalert N. Psoriasis registry in public health hospital. J Med Assoc Thai. 2013;96(8):960-966.

10. Chen YJ, Wu CY, Chen TJ, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011;65(1):84-91. doi:10.1016/j.jaad.2010.04.046.

11. Boffetta P, Gridley G, Lindelöf B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol. 2001;117(6):1531-1537. doi:10.1046/j.0022-202x.2001.01520.x.

12. Sroa N, Witman P. Howel-Evans syndrome: a variant of ectodermal dysplasia. Cutis. 2010;85(4):183-185.

13. Asgari MM, Ray GT, Geier JL, Quesenberry CP. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017;76(4):632-638. doi:10.1016/j.jaad.2016.10.006.

14. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):36-46. doi:10.1111/jdv.12165.

15. Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933-7943. doi:10.3748/wjg.v21.i26.7933.

16. Herbella FA, Patti MG, Takassi GF. Skin metastases from esophageal and esophagogastric junction cancer. J Gastrointest Oncol. 2011;2(2):104-105. doi:10.3978/j.issn.2078-6891.2011.007.

17. Iwanski GB, Block A, Keller G, et al. Esophageal squamous cell carcinoma presenting with extensive skin lesions: a case report. J Med Case Rep. 2008;2:115. doi:10.1186/1752-1947-2-115.

18. Iftikhar I, Abdelmannan D, Daw HA. Dermatomyositis and esophageal cancer. South Med J. 2006;99(7):777-779. doi:10.1097/

19. Cho JH, Kim NJ, Ko SM, et al. A case report of paraneoplastic pemphigus associated with esophageal squamous cell carcinoma. Cancer Res Treat. 2013;45(1):70-73. doi:10.4143/crt.2013.45.1.70.

20. Rodrigues IA Jr, Gresta LT, Cruz RC, Carvalho GG, Moreira MH. Bazex syndrome. An Bras Dermatol. 2013;88(6 Suppl 1):209-211. doi:10.1590/abd1806-4841.20132488.

21. Silva JA, Mesquita Kde C, Igreja AC, et al. Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol. 2013;88(1):9-22. doi:10.1590/S0365-05962013000100001.